期刊
CLINICAL IMMUNOLOGY
卷 191, 期 -, 页码 110-115出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2017.11.014
关键词
Hypogammaglobulinemia; Infections; Multiple myeloma; Quality of life; Subcutaneous immunoglobulin
类别
资金
- Italian Association for Cancer Research (AIRC, Milan) [14095]
- five per thousand Molecular Clinical Oncology Special Program [9965]
- European Commission's 7th Framework Programme (EU FPT7) [278706]
- MIUR PRIN [2009WCNS5C_004, 2010NECHBX]
Multiple myeloma is commonly associated with a reduction of non-paraprotein immunoglobulins, resulting in a higher risk of infections that represent the leading cause of the patients' death. Therefore, immunoglobulin replacement therapy appears a logical approach. A total number of 46 myeloma patients were randomly enrolled: 24 of them were assigned to receive subcutaneous immunoglobulins, and 22 were controls. The primary endpoint was the evaluation of the annual rate of severe infections in immunoglobulins-receiving patients as compared with those untreated. Subcutaneous immunoglobulins-treated patients showed a significantly lower number of severe infections per year. Adverse events were limited to the site of infusion and were easily manageable. Health-related quality of life was significantly better in subcutaneous immunoglobulins-receiving patients. By decreasing the rate of infections, the prophylactic administration of SCIg improves both adherence to chemotherapy and health-related quality of life, and is cost-effective by reducing the need of hospitalization and the use of antibiotics. (C) 2017 Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据